首页> 外国专利> GALECTINS CONTROL MTOR IN RESPONSE TO ENDOMEMBRANE DAMAGE AND PROVIDE A MECHANISM AND TARGET FOR THE TREATMENT OF AUTOPHAGY-RELATED DISEASES

GALECTINS CONTROL MTOR IN RESPONSE TO ENDOMEMBRANE DAMAGE AND PROVIDE A MECHANISM AND TARGET FOR THE TREATMENT OF AUTOPHAGY-RELATED DISEASES

机译:Galectins控制MTOR响应于EndoMembrane损伤并提供了治疗自噬相关疾病的机制和靶标

摘要

The present invention is directed to the discovery that Galectins and in particular, Galectin-8 and Galectin-9 control mTor response (Galectin-8 is a mTOR inhibitor and Galectin-9 is modulator/upregulator of AMPKinase) to endomembrane damage and these compositions can be used, either alone or together, optionally in combination with a lysomotropic agent and other bioactive agents as compositions for the treatment of autophagy-elated diseases. The present invention is directed to pharmaceutical compositions and methods for treating autophagy-related diseases as described herein.
机译:本发明旨在发现半乳糖素,特别是半乳糖素-8和半乳糖蛋白-9对照MTOR响应(Galectin-8是MTOR抑制剂和Galectin-9是Ampkinase的调节剂/上限),并可以可选地或一起使用,任选地与糖磷酸酯和其他生物活性剂组合作为用于治疗自噬泻药疾病的组合物。本发明涉及如本文所述治疗自噬相关疾病的药物组合物和方法。

著录项

  • 公开/公告号US2021069295A1

    专利类型

  • 公开/公告日2021-03-11

    原文格式PDF

  • 申请/专利权人 STC. UNM;

    申请/专利号US201816977318

  • 发明设计人 VOJO P. DERETIC;JINGYUE JIA;

    申请日2018-11-09

  • 分类号A61K38/17;A61K31/4706;A61K38/05;A61K31/133;A61K31/16;A61K31/4164;A61K31/7016;C07K16/28;A61K31/732;A61K31/4745;A61K31/52;A61K31/436;A61K31/675;A61K31/437;A61K31/353;A61K31/522;A61K31/12;A61K31/05;

  • 国家 US

  • 入库时间 2022-08-24 17:39:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号